Welcome to the PharmCast Research Store. Gain access to market leading research in your industry. You can browse through the portfolio of reports below or enter keywords in the search box to find the information you have been looking for.
  • Browse Reports & Briefs
  • Browse Company Profiles
  • Browse Industry Profiles
  • Latest News
Number of Employees

< 250 (30)

250 - 999 (22)

1,000 - 2,499 (20)

2,500 - 4,999 (29)

5,000 - 9,999 (56)

10,000 - 49,999 (113)

50,000+ (40)

Annual Revenue US$m

< 50 (19)

50 - 99 (7)

100 - 199 (8)

200 - 499 (20)

500 - 999 (11)

1,000 - 1,999 (45)

2,000+ (189)

Top stories

Sandoz unveils generic version of cystic fibrosis medication in US

Sandoz has announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI, currently marketed by Novartis Pharmaceuticals Corporation. Tobramycin inhalation solution, USP is indicated for the management of cystic fibrosis patients whose lungs contain bacteria called P. aeruginosa...more >>

ACADIA Pharmaceuticals announces senior executive appointments

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, has appointed Stephen Davis as executive vice president, or EVP, CFO and chief business officer. Mr Davis will report to Uli Hacksell, CEO of the company...more >>

Agilent Technologies unveils new molecular solution

Agilent Technologies Inc., a provider of bio-analytical and electronic measurement solutions, has unveiled a molecular solution that combines its Oligo Library Synthesis capability for FISH, or fluorescence in situ hybridization, with its SureDesign online application to produce custom FISH probes...more >>

Peregrine Pharmaceuticals Q4 net loss up

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, has reported that the net loss attributable to common stockholders for the fourth quarter ended April 30, 2014 was $10.65 million, or $0.06 loss per share, compared to a net loss attributable to common stockholders of $8.45 million, or $0.06 loss per share, for the fourth quarter April 30, 2013...more >>